Home > News > NanoCure Changes Name to Avidimer Therapeutics
May 17th, 2005
NanoCure Changes Name to Avidimer Therapeutics
Abstract:
James R. Baker, Jr., M.D., Avidimer's chairman and chief scientific officer, commented, "The name Avidimer Therapeutics refers to our focus on cell-specific targeting of therapeutics and diagnostics through the use of novel branch-like polymers known as dendrimers, which avidly target diseased cells and have the potential to diagnose and treat cancer and other diseases more effectively and completely than current diagnostics and therapeutics. Their small size (less than 5nm) enables them to escape the blood stream through vascular pores, selectively target and treat tumor cells, and be cleared rapidly through the kidney. Preclinical studies have demonstrated the impressive ability of dendrimers to target diseased cells in the body."
Source:
genengnews.com
Bookmark:
Nanomedicine
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013